TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

BACKGROUND: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic characteristics of TRK fusion-...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Rosen, Ezra Y., Goldman, Debra A., Hechtman, Jaclyn F., Benayed, Ryma, Schram, Alison M, Cocco, Emiliano, Shifman, Sophie, Gong, Yixiao, Kundra, Ritika, Solomon, James P., Bardelli, Alberto, Scaltriti, Maurizio, Drilon, Alexander, Iasonos, Alexia, Taylor, Barry S., Hyman, David M.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124988/
https://ncbi.nlm.nih.gov/pubmed/31871300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3165
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items